Michael Gelband’s Celldex Therapeutics CLDX Stock Holding History

Michael Gelband’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-17,244	Closed	-$436K	–	1522
2024 Q4	$436K	Buy	+17,244	New	+$469K	﹤0.01%	1184
2024 Q3	–	Sell	-38,150	Closed	-$1.41M	–	1674
2024 Q2	$1.41M	Buy	+38,150	New	+$1.44M	0.01%	909
2023 Q4	–	Sell	-26,434	Closed	-$727K	–	1538
2023 Q3	$727K	Buy	+26,434	New	+$829K	0.01%	1092
2021 Q2	–	Sell	-135,552	Closed	-$2.79M	–	2400
2021 Q1	$2.79M	Sell	135,552 -35,039	-21%	-$805K	0.04%	445
2020 Q4	$2.99M	Buy	+170,591	New	+$3.07M	0.03%	398
2020 Q3	–	Sell	-58,415	Closed	-$759K	–	1800
2020 Q2	$759K	Buy	+58,415	New	+$259K	0.02%	880

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's CLDX Position: Q1 2025 in Review

Michael Gelband sold out of Celldex Therapeutics (CLDX) in Q1 2025, closing a stake of 17,244 shares — an estimated $436K sold.

Michael Gelband first reported a position in CLDX in Q2 2020 and held it in 6 quarters. The position peaked at $2.99M in Q4 2020. 171 funds tracked by Wall St. Rank hold CLDX as of Q1 2025.

Michael Gelband reported no remaining Celldex Therapeutics position as of Q1 2025 after selling out during the quarter.
Michael Gelband sold 17,244 Celldex Therapeutics shares in Q1 2025, an estimated $436K.
Michael Gelband first reported a position in Celldex Therapeutics in Q2 2020 and held it in 6 quarters.
Michael Gelband's Celldex Therapeutics position peaked at $2.99M in Q4 2020.
171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2025.

Based on ExodusPoint Capital Management's 13F filing for Q1 2025, filed 14 May 2025.